natgillin/translations-raw huggingface dataset:
Pneumokok polysaccharid serotype 6B1 4,4 µg
Pneumococcal polysaccharide serotype 6B1 4.4 µg
Pneumokok polysaccharid serotype 7F1 2,2 µg
Pneumococcal polysaccharide serotype 7F1 2.2 µg
Pneumokok polysaccharid serotype 9V1 2,2 µg
Pneumococcal polysaccharide serotype 9V1 2.2 µg
Pneumokok polysaccharider
Pneumococcal Polysaccharides
Pneumokokpolysaccharid serotype 1* 1 1 mikrogram
Pneumococcal polysaccharide serotype 1* 1 1 microgram
Pneumokokpolysaccharid serotype 11,2 1 mikrogram
Pneumococcal polysaccharide serotype 11,2 1 microgram
Pneumokokpolysaccharid serotype 14* 1 1 mikrogram
Pneumococcal polysaccharide serotype 14* 1 1 microgram
Pneumokokpolysaccharid serotype 141,2 1 mikrogram
Pneumococcal polysaccharide serotype 141,2 1 microgram
Pneumokokpolysaccharid serotype 18C* 2 3 mikrogram
Pneumococcal polysaccharide serotype 18C* 2 3 micrograms
Pneumokokpolysaccharid serotype 18C1,3 3 mikrogram
Pneumococcal polysaccharide serotype 18C1,3 3 micrograms
Pneumokokpolysaccharid serotype 19F* 3 3 mikrogram
Pneumococcal polysaccharide serotype 19F* 3 3 micrograms
Pneumokokpolysaccharid serotype 19F1,4 3 mikrogram
Pneumococcal polysaccharide serotype 19F1,4 3 micrograms
Pneumokokpolysaccharid serotype 23F* 1 1 mikrogram
Pneumococcal polysaccharide serotype 23F* 1 1 microgram
Pneumokokpolysaccharid serotype 23F1,2 1 mikrogram
Pneumococcal polysaccharide serotype 23F1,2 1 microgram
Pneumokokpolysaccharid serotype 4* 1 3 mikrogram
Pneumococcal polysaccharide serotype 4* 1 3 micrograms
Pneumokokpolysaccharid serotype 41,2 3 mikrogram
Pneumococcal polysaccharide serotype 41,2 3 micrograms
Pneumokokpolysaccharid serotype 5* 1 1 mikrogram
Pneumococcal polysaccharide serotype 5* 1 1 microgram
Pneumokokpolysaccharid serotype 51,2 1 mikrogram
Pneumococcal polysaccharide serotype 51,2 1 microgram
Pneumokokpolysaccharid serotype 6B* 1 1 mikrogram
Pneumococcal polysaccharide serotype 6B* 1 1 microgram
Pneumokokpolysaccharid serotype 6B1,2 1 mikrogram
Pneumococcal polysaccharide serotype 6B1,2 1 microgram
Pneumokokpolysaccharid serotype 7F* 1 1 mikrogram
Pneumococcal polysaccharide serotype 7F* 1 1 microgram
Pneumokokpolysaccharid serotype 7F1,2 1 mikrogram
Pneumococcal polysaccharide serotype 7F1,2 1 microgram
Pneumokokpolysaccharid serotype 9V* 1 1 mikrogram
Pneumococcal polysaccharide serotype 9V* 1 1 microgram
Pneumokokpolysaccharid serotype 9V1,2 1 mikrogram
Pneumococcal polysaccharide serotype 9V1,2 1 microgram
Pneumoni
2.2 Pneumonia
Pneumoni
pneumonia
pneumoni
Rash
Pneumoni (1,6 %) (G3/4: 1,0 %)
Pneumonia (1.6%) (G3/4: 1.0%)
Pneumoni (bakterie-, virus- og svampeinfektioner, herunder opportunistiske infektioner)
Pneumonia (bacterial, viral and fungal infections, including opportunistic infections)
pneumoni (inklusive bakteriel, viral og mykotisk), øvre luftvejsinfektion/inflammation, herpes virus infektion, enterocolitis, sepsis (inklusive ikke almindelige tilfælde med dødelig udgang)
pneumonia (including bacterial, viral, and fungal), upper respiratory tract infection/inflammation, herpes virus infection, enterocolitis infection, sepsis (including uncommon cases with fatal outcomes)
Pneumoni (lungebetændelse)
pneumonia (infection of the lungs)
Pneumoni (lungebetændelse)
pneumonis (infection of the lungs)
Pneumoni (lungebetændelse).
pneumonia (infection of the lungs)
Pneumoni af grad 3 eller derover forekom hyppigere hos ældre patienter behandlet med IMBRUVICA (13 % hos patienter ≥ 65 versus 7 % hos patienter < 65).
Grade 3 or higher pneumonia occurred more frequently among elderly patients treated with IMBRUVICA (13% of patients age ≥ 65 versus 7% of patients < 65 years of age).
Pneumoni blev oftest observeret hos patienter med transformeret CML og hos patienter med GIST.
Pneumonia was reported most commonly in patients with transformed CML and in patients with GIST.
Pneumoni er den hyppigste kliniske manifestation af pneumokoksygdom hos voksne.
Pneumonia is the most common clinical presentation of pneumococcal disease in adults.
Pneumoni Gastroenteritis Urinvejsinfektion Virusinfektion Sinusitis
Pneumonia Gastroenteritis Urinary tract infection Viral infection Sinusitis
Pneumoni hos patienter med KOL
Pneumonia in patients with COPD
Pneumoni Influenza Nasopharyngitis Øreinfektion Sinusitis Rhinitis
Pneumonia Influenza Nasopharyngitis Ear infection Sinusitis Rhinitis
Pneumoni Luftvejsinfektion Nasofaryngitis
Pneumonia Respiratory tract infection Nasopharyngitis
Pneumoni*
Decreased appetite
Pneumoni*
Pneumonia
pneumoni* (herunder forårsaget af bakterier, virus eller svampe), nasopharyngitis
pneumonia* (including bacterial, viral and fungal), nasopharyngitis
Pneumoni*#
Pneumonia*#
Pneumoni**
Pneumonia
Pneumoni,
Pneumonia;
Pneumoni, askariose, enterobiasis, herpes zoster, cellulitis, urinvejsinfektion, gastroenteritis
Pneumonia, ascariasis, enterobiasis, herpes zoster, cellulitis, urinary tract infection, gastroenteritis
Pneumoni, luftvejsinfektion, cystitis, infektion i øret, tonsillitis
pneumonia, respiratory tract infection, cystitis, ear infection, tonsillitis
Pneumoni, mild eller moderat (se pkt.
Community-acquired pneumonia, mild or moderate,
pneumoni, sepsis, folliculitis
pneumonia, sepsis, folliculitis
Pneumoni, øget legemstemperatur, letargi, erytem, visuelle hallucinationer og urininkontinens blev almindeligt observeret (1-10 %).
Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.
Pneumoni, øget legemstemperatur, letargi, erytem, visuelle hallucinationer og urininkontinens blev almindeligt observeret (1-10%).
Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.
Pneumoni, øsofagal candidiasis
Pneumonia, oesophageal candidiasis
Pneumoni1
pneumonia1
Pneumoni: 800 mg én gang daglig i 7-10 dage
Community-acquired pneumonia: 800 mg once a day for 7 to 10 days,
Pneumonia (herunder interstitiel pneumoni)
Pneumoniaa (including interstitial pneumonia)
pneumonia, bronkitis
pneumoniaa, bronchitis
pneumonia, infektion i øvre luftveje
pneumoniaa, upper respiratory tract infection
Pneumonib
Pneumoniab
Pneumonic
Pneumoniac
Pneumonitis
Pneumonitis (ILD)
pneumonitis
pneumonitis,
pneumonitis (interstitiel lungesygdom)
pneumonitis (interstitial lung disease)
Pneumonitis af
Anhidrosis
Pneumonitis af
Hypersensitivity-type
Pneumonitis af
Pruritus
Pneumonitis c, næseblod, hoste
Pneumonitis c, epistaxis, cough
Pneumonitis er rapporteret hos et lille antal patienter, der fik olaparib, og nogle rapporter var fatale.
Pneumonitis has been reported in a small number of patients receiving olaparib, and some reports have been fatal.
Pneumonitis gik over hos 55 patienter.
Pneumonitis resolved in 55 patients.
Pneumonitis medførte seponering af pembrolizumab hos 36 (1,3%) patienter.
Pneumonitis led to discontinuation of pembrolizumab in 36 (1.3%) patients.
pneumonitis,
pneumonitis
pneumonitis,
System Organ Class
pneumonitis, dyspnø, hoste
pneumonitis, dyspnoea, cough
pneumonitis, pleuraeffusion1)
pleural effusion1)
pneumonitisa,b, dyspnø, hoste
pneumonitisa,b, dyspnoea, cough
pneumonitisa,b, lungeembolia, dyspnø, hoste
pneumonitisa,b, pulmonary embolisma, dyspnoea, cough
pneumonitisf, dyspnø, hoste
pneumonitisf, dyspnea, cough
Pneumothorax,
disorders
Pneumothorax,
thoracic and
PNH
aHUS
PNH resulterer i anæmi (lavt antal røde blodlegemer), tromboser (blodpropper i blodkarrene), pancytopeni (lavt antal blodlegemer) og mørk urin, mens aHUS resulter i anæmi, trombocytopeni (fald i antallet af blodplader, som hjælper blodet til at størkne) og nyresvigt.
PNH results in anaemia (low red blood cell counts), thrombosis (blood clots in the blood vessels), pancytopenia (low counts of blood cells) and dark urine, while aHUS results in anaemia, thrombocytopenia (a decrease in the number of platelets, components that help the blood to clot) and kidney failure.
PNH- og aHUS-patienter under 18 år skal have lavere doser, der beregnes efter deres kropsvægt, og som indgives over 1 til 4 timer.
PNH and aHUS patients under 18 years old receive lower doses based on their body weight, administered over 1 to 4 hours.
Población pediátrica
Paediatric population
Poco frecuentes:
Uncommon:
Podagra/Urinsyregigt
Gout/Gouty Arthritis
pointes ved brug af methadon (se
Pointes have been reported with methadone
Poisson- regression
Poisson regression
Polio kan medføre at musklerne ikke kan bevæges (paralyse).
Polio can make the muscles unable to move (paralysis).
Polio  en virusfremkaldt infektion.
Polio - a viral infection.
Polio: en virusfremkaldt infektion.
Polio: a viral infection.
Poliomyelitis (ofte bare polio eller børnelammelse) stammer fra virus, der påvirker nerverne.
Poliomyelitis (often just called polio) is caused by viruses that affect the nerves.
Poliomyelitis (ofte bare polio eller børnelammelse): Stammer fra virus, der påvirker nerverne.
Poliomyelitis (often just called polio): caused by viruses that affect the nerves.
poliomyelitis (polio, en sygdom, der angriber nerverne og kan medføre muskelsvaghed eller - lammelse) invasive sygdomme (såsom meningitis) forårsaget af bakterien H. influenzae type b.
poliomyelitis (polio, a disease that affects the nerves and can lead to muscle weakness or paralysis); invasive diseases (such as meningitis) caused by H. influenzae type b bacteria.
poliovira (type 1, 2 og 3), der er blevet inaktiveret (dræbt), så de ikke er sygdomsfremkaldende, polysakkarider udvundet af de ”kapsler”, der omgiver Hib-bakterien.
polioviruses (types 1, 2 and 3) that have been inactivated (killed) so they do not cause any disease; polysaccharides extracted from the ‘capsules’ that surround the Hib bacteria.
poliovira (type 1, 2 og 3), der er blevet inaktiveret (dræbt), så de ikke er sygdomsfremkaldende.
polioviruses (types 1, 2 and 3) that have been inactivated (killed) so that they do not cause any disease.
Poliovirus (inaktiveret) type 1 (mahoney-stamme)4 40 antigen D unit type 2 (MEF-1-stamme)4 8 antigen D unit type 3 (Saukett-stamme)4 32 antigen D unit
Poliovirus (inactivated) type 1 (Mahoney strain)4 40 D-antigen unit type 2 (MEF-1 strain) 4 8 D-antigen unit type 3 (Saukett strain) 4 32 D-antigen unit
Poliovirus (inaktiveret) type 1, 2, 3 40, 8, 32 DE
Poliovirus (inactivated) type 1, 2, 3 40, 8, 32 DU
Poliovirus (inaktiveret) type 1, 2, 3 40, 8, 32 DU
Poliovirus (inactivated) type 1, 2, 3 40, 8, 32 DU
Poliovirus (inaktiveret) type 1/2 /3
Poliovirus (Inactivated) Types 1/2/3
Poliovirus (inaktiveret) type 1/2/3 40/8/32 DE
Poliovirus (Inactivated) Types 1/2/3 40/8/32 DU
Poliovirus (inaktiveret)3
Poliovirus (Inactivated)3
Pollakisuri
disease
Pollakisuri
Grade>3 n (%)
poloxamer 188 benzylalkohol vand til injektionsvæsker
poloxamer 188 benzyl alcohol water for injections
Poloxamer 188 Magnesiumstearat Vinsyre (E334)
Poloxamer 188 Magnesium stearate Tartaric acid (E334)
poloxamer 188 phenol vand til injektionsvæsker
poloxamer 188 phenol water for injections
Poloxamer 188 Povidon K-30
Poloxamer 188 Povidone K-30
Poloxamer 188 Saccharose Methionin
Poloxamer 188 Sucrose Methionine
Poloxamer 188, saccharose, methionin, dinatriumhydrogenphosphatdihydrat, natriumdihydrogenphosphatdihydrat, phosphorsyre og vand til injektionsvæsker.
Poloxamer 188, sucrose, methionine, disodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate dihydrate, phosphoric acid and water for injections.
Poloxamer Mannitol (E421) Crospovidon
Poloxamer Mannitol (E421) Crospovidone
Polska
Italia
Polska
Κύπρος
Polska sanofi-Aventis Sp. z o.o.
Polska sanofi-aventis Sp . z o.o.
Polte og gylte: En injektion, der efterfølges af en anden injektion 3-4 uger senere, mindst 2 uger før løbning.
Gilts: One injection, followed 3 to 4 weeks later by a second injection, at least 2 weeks before mating.
Polte, gylte og søer: 25 doser, smågrise: 100 doser.
Sows: 25 doses, piglets: 100 doses
Polte, gylte og søer: 5 doser, smågrise: 20 doser.
Sows: 5 doses, piglets: 20 doses
Polte, gylte og søer: Administrer 1 dosis på 2 ml ved dyb intramuskulær injektion i henhold til følgende vaccinationsprogram:
Gilts and sows: Administer one 2 ml dose by deep intramuscular injection in accordance with the following vaccination scheme:
poly(butylmethacrylat, methylmethacrylat) akryl-co-polymer.
poly(butylmethacrylate, methylmethacrylate), acrylic copolymer.
Poly(D,L-lactid-co-glycolid) (50-60:40-50)
Poly(D,L-lactide-co-glycolide) (50-60:40-50)
Poly(D,L-lactid-co-glycolid) (50:50) Solvens
Poly(D,L-lactide-co-glycolide) (50:50) Solvent
Poly(DL-lactid-co-glycolid)
Poly (DL-lactide-co-glycolide).
Polyamid/Al/PVC - Aluminiumsfolieblister
Polyamide/Al/PVC - Aluminium foil blister
Polyamid/aluminium/ PVC-blisterpakninger
blister OPA/alu/ PVC
Polyamid/aluminium/PVC blisterpakning 14 tabletter
Aluminium/aluminium blisters (PA/PA/Al/PVC/Al).
Polyamid/aluminium/PVC-blisterpakning 14 tabletter
Aluminium/aluminium blisters (PA/PA/Al/PVC/Al).
Polyartikulær juvenil idiopatisk artrit fra 13 år
Polyarticular juvenile idiopathic arthritis from 13 years of age
Polyartikulær juvenil idiopatisk artrit fra 13 år.
Polyarticular juvenile idiopathic arthritis from 13 years of age
Polyartikulær juvenil idiopatisk artrit fra 2 til 12 år
Polyarticular juvenile idiopathic arthritis from 2 to 12 years of age
Polyartikulær juvenil idiopatisk artrit fra 2-12 år.
Polyarticular juvenile idiopathic arthritis from 2 to 12 years of age
Polyartikulær juvenil idiopatisk artrit fra 2-12 år:
Polyarticular juvenile idiopathic arthritis from 2 to 12 years of age
Polyartikulær juvenil idiopatisk artrit hos børn fra 2 til 12 år
Polyarticular juvenile idiopathic arthritis from 2 to 12 years of age
Polyartikulær juvenil idiopatisk artrit og entesopati-relateret artrit er sygdomme med betændelseslignende (inflammatoriske) reaktioner i leddene.
Polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis are inflammatory diseases.
Polyartrit (ledbetændelse i 5 eller flere led) (reumafaktor-positiv eller -negativ) og udvidet oligoartrit (ledbetændelse i 2-4 led de første 6 måneder af sygdommen, men med senere øgning til 5 eller flere led) hos patienter fra 2 år.
Polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in patients from the age of 2 years
Polychlorotrifluoroethylen (PCTFE)/PVC/Alu blister
Polychlorotrifluoroethylene (PCTFE)/PVC/Alu blister
Polycystisk ovariesyndrom (PCOS).
Polycystic ovarian syndrome (PCOS).
Polycythæmia vera er en sygdom, som primært fører til en overproduktion af røde blodceller, hvilket kan reducere blodtilførslen til organerne, da blodet ”fortykkes”, og undertiden medføre dannelse af blodpropper.
Polycythaemia vera is a disease that mainly causes too many red blood cells to be produced, which can cause reduced blood flow to the organs due to ‘thickening’ of the blood and occasionally the formation of blood clots.
Polycytæmic
Polycythaemiac
polydipsi, dehydrering, hyperkaliæmi, hyperglykæmi, nedsat appetit
polydipsia, dehydration, hyperkalaemia, hyperglycaemia, decreased appetite
polydipsi, forhøjet
hyperinsulinaemia
polydipsi, forhøjet
insomniae
Polyester og ethylvinylacetat
Polyester and ethyl vinyl acetate
Polyethylen (HDPE)-flaske med 20 ml (10 doser), 100 ml (50 doser) eller 250 ml (125 doser), forseglet med gummiprop og sikret med en hætte af aluminium.
Polyethylene (HDPE) bottle of 20 ml (10 doses), 100 ml (50 doses) or 250 ml (125 doses) sealed with a rubber closure and secured with an aluminium cap.
Polyethylen (PE)/aluminium (Al)/polyethylen (PE) laminerede plasttuber med et HDPE-hoved (højdensitet polyethylen) og et børnesikret PP-lukke (polypropylen).
Polyethylene (PE)/Aluminium (Al)/ Polyethylene (PE) laminated plastic tubes with a high density polyethylene (HDPE) head and polypropylene (PP) child resistant closure.
Polyethylen (PE)/aluminium (Al)/polyethylen (PE) laminerede plasttuber med et HDPE-hoved (højdensitet polyethylen) og et PP-lukke (polypropylen).
Polyethylene (PE)/Aluminium (Al)/ Polyethylene (PE) laminated plastic tubes with a high density polyethylene (HDPE) head and polypropylene (PP) closure.
Polyethylen (PE)/aluminium (Al)/polyethylen (PE) laminerede plasttuber: EU/1/13/904/001
Polyethylene (PE)/Aluminium (Al)/ Polyethylene (PE) laminated plastic tubes: EU/1/13/904/001
Polyethylen (PE)/copolymer/aluminium (Al)/copolymer/polyethylen (PE) polyethylenlaminerede aluminiumstuber (polyfoil) med et HDPE-hoved (højdensitet polyethylen) og et børnesikret PE-lukke (polyethylen).
Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil plastic tubes (kind of laminate) with a high density polyethylene (HDPE) head and polyethylene (PE) child resistant closure
Polyethylen (PE)/copolymer/aluminium (Al)/copolymer/polyethylen (PE) polyethylenlaminerede aluminiumstuber (polyfoil) med et HDPE-hoved (højdensitet polyethylen) og et børnesikret PP-lukke (polypropylen).
Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil plastic tubes (kind of laminate) with a high density polyethylene (HDPE) head and polypropylene (PP) child resistant closure.
Polyethylen (PE)/copolymer/aluminium (Al)/copolymer/polyethylen (PE) polyethylenlaminerede aluminiumstuber (polyfoil):
Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil plastic tubes: EU/1/13/904/004
Polyethylen flaske
Bottle (polyethylene)
Polyethylen flaske
Polyethylene
Polyethylen flaske
Polyethylene bottle
Polyethylen flaske indeholdende 10 ml, 15 ml eller 30 ml med polyethylen dråbeanordning og en børnesikret lukning.
Polyethylene bottle containing 10 ml, 15 ml or 30 ml with a polyethylene dropper and a tamper proof child resistant closure.
Polyethylen flaske med en chlorobutyl gummiprop og aluminiumshætte.
Polyethylene bottle with a chlorobutyl elastomer closure and aluminium cap.
Polyethylen flaske med en chlorobutyl gummiprop og aluminiumshætte.
Polyethylene bottles with a chlorobutyl elastomer closure and aluminium cap.
Polyethylen terephtalat- flaske, HDPE/LDPE hætte, polypropylen/polyethylen- målesprøjte
Polyethylene terephthalate bottle, HDPE/LDPE cap, polypropylene / polyethylene measuring syringe
Polyethylen terephtalat- flaske, HDPE/LDPE hætte, polypropylen/polyethylen- målesprøjte.
Polyethylene terephthalate bottle, HDPE/LDPE cap, polypropylene / polyethylene measuring syringe.
Polyethylen- terepthalat (PET) hætteglas, med gummiprop og aluminiumshætte
Polyethylene terephthalate (PET) vials with rubber stopper and aluminium cap
Polyethylen- terepthalat (PET) hætteglas, med gummiprop og aluminiumshætte
Polyethylene terephthalate (PET) vials, with rubber stopper and aluminium cap
Polyethylen- terepthalat (PET) hætteglas, med gummiprop og aluminiumshætte
Polyethylene terephthalate (PET) vials, with rubber stopper and aluminium cap‌
Polyethylen- terepthalat (PET) hætteglas, med gummiprop og aluminiumshætte
Polyethylene terepphthalate (PET) vials, with rubber stopper and aluminium cap
Polyethylen-flaske indeholdende 10 ml, 32 ml, 100 ml eller 180 ml med polyethylen-dråbeanordning og en børnesikret lukning.
Polyethylene bottle containing 10 ml, 32 ml, 100 ml or 180 ml with a polyethylene dropper and a tamper proof child resistant closure.
Polyethylen-flaske indeholdende 15 ml eller 30 ml med polyethylen-dråbeanordning og en børnesikret lukning.
Polyethylene bottle containing 15 ml or 30 ml with a polyethylene dropper and a tamper proof child resistant closure.
Polyethylen-flaske indeholdende 5 ml, 10 ml eller 25 ml med en børnesikret lukning og en polypropylen-doseringssprøjte.
Polyethylene bottle containing 5 ml, 10 ml or 25 ml with a tamper proof child resistant closure and a polypropylene measuring syringe.
Polyethylen-flaske med høj densitet og børnesikret polyethylen-skruelåg med høj densitet.
High density polyethylene bottle with high density polyethylene tamper evidence screw cap.
Polyethylen-sprøjteansats med lav densitet til polypropylen-doseringssprøjter.
Low density polyethylene syringe insert for the polypropylene measuring syringes.
Polyethylenflaske med 20 ml (10 doser), 100 ml (50 doser) eller 250 ml (125 doser), forseglet med gummilukke og sikret med en hætte af aluminium.
Polyethylene bottle of 20 ml (10 doses), 100 ml (50 doses) or 250 ml (125 doses) sealed with a rubber closure and secured with an aluminium cap.
Polyethylenflaske med børnesikret polypropylenlåg indeholdende 50, 150 eller 480 ml pr. flaske.
PET-bottles with polypropylene child-resistant closure containing 50, 150 or 480 ml per bottle.
Polyethylenflaske med gummiprop og sikret med en hætte af aluminium
Polyethylene bottle with rubber closure and aluminium cap
Polyethylenglycol 3350
Polyethylene glycol 3350
Polyethylenglykol 400 (kun 1,5 mg, 6 mg , 9 mg og 12 mg tabletter) Jernoxid (gul) (E172) (kun 1,5 mg, 6 mg og 12 mg tabletter) Jernoxid (rød) (E172) (kun 1,5 mg, 6 mg og 9 mg tabletter) Lactosemonohydrat (kun 3 mg tabletter)
Polyethylene glycol 400 (1.5, 6, 9 and 12 mg tablet only) Ferric Oxide (Yellow) (E172) (1.5, 6, 12 mg tablet only) Ferric Oxide (Red) (E172) (1.5, 6, 9 mg tablet only) Lactose monohydrate (3 mg tablet only)
Polyethylenterephthalat-flakse indeholdende 15 eller 30 ml med to polyethylen/polypropylen- målesprøjter.
Polyethylene terephthalate bottle containing 15 or 30 ml with two polyethylene/polypropylene measuring syringes.
Polyetylen/aluminium/polyethylen –tereftalat folie brevet.
Polyethylene/aluminium/polyethylene terephthalate foil sachet.
Polyglyceryloleat Renset vand
Polyglyceryl oleate Purified water
Polymikrobiale intra- abdominale infektioner har dog responderet på behandling med tigecyclin i kliniske undersøgelser.
However, polymicrobial intra-abdominal infections have shown to respond to treatment with tigecycline in clinical trials.
polymyalgia rheumatica, artritis
polymyalgia rheumatica, arthritis
polyneuropati
polyneuropathy
Polyoxy- ethylensorbita n-monooleat og -trioleat
Polyoxyethylen e sorbitan monooleate and trioleate
Polyoxyethylen fede syrer
Polyoxyethylene fatty acids
Polyoxyl-ricinusolie Citronsyre (vandfri) Ethanol
Polyoxyl castor oil Citric acid (anhydrous) Ethanol
polyoxyleret (40) hydrogeneret ricinusolie,
polyoxyl 40 hydrogenated castor oil,
Polyoxyleret ricinusolie Ethanol
Capsule contents Macrogolglycerol ricinoleate Ethanol
Polyoxyleret, hydrogeneret ricinusolie (HCO-40).
Polyoxyethylene hydrogenated castor oil 40 (HCO-40).
Polyoxyleret, hydrogeneret ricinusolie 40 (HCO-40) Borsyre (E284)
Polyoxyethylene hydrogenated castor oil 40 (HCO-40) Boric acid (E284)
Polypropylen flaske indeholdende 3 ml med polyethylen dråbeanordning og en børnesikret lukning.
Polypropylene bottle containing 3 ml with a polyethylene dropper and a tamper proof child resistant closure.
Polypropylen flaske med butyl elastomerprop
Polypropylene bottle with butyl elastomere closure
Polypropylen flaske à 50 eller 100 ml med butylelastomer-prop.
Polypropylene bottle of 50 or 100 ml with butyl elastomer closure.
polypropylen polyethylen-belagt PVC polyurethan
polypropylene polyethylene lined PVC polyurethane
Polypropylenflaske Flaske á 10 og 25 doser
Polypropylene bottle Bottle of 10 or 25 doses
Polypropylenflaske med en butylelastomer prop der er forseglet med en aluminiumshætte.
Polypropylene bottle with a butyl elastomer closure and sealed with an aluminium cap.
Polyquaternium-1, polyoxyleret, hydrogeneret ricinusolie 40 (HCO-40), borsyre, mannitol, natriumchlorid, propylenglycol, natriumhydroxid og/eller hydrogenchloridsyre (til at justere pH) og renset vand.
Polyquaternium-1, polyoxyethylene hydrogenated castor oil 40 (HCO-40), boric acid, mannitol, sodium chloride, propylene glycol, sodium hydroxide and/or hydrochloric acid (to adjust pH) and purified water.
Polyribosylribitolphosphat (PRP) fra Haemophilus influenzae type b som PRP-OMPC 7,5 µg
Polyribosylribitol phosphate (PRP) from Haemophilus influenzae type b as PRP-OMPC 7.5 µg
Polysacchariderne er blevet renset og derefter "konjugeret" (fastgjort) til en bærer, så immunsystemet bedre kan genkende dem.
These polysaccharides have been purified, then ‘conjugated’ (attached) to a carrier to help them to be recognised by the immune system.
Polysakkariderne er blevet renset og derefter fastgjort (konjugeret) til en bærer, for at immunsystemet bedre kan genkende dem.
These polysaccharides have been purified, then ‘conjugated’ (attached) to a carrier to help them to be recognised by the immune system.